Compare IMAX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | DAWN |
|---|---|---|
| Founded | 1967 | 2018 |
| Country | Canada | United States |
| Employees | N/A | 181 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1997 | 2021 |
| Metric | IMAX | DAWN |
|---|---|---|
| Price | $40.68 | $21.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $44.44 | $27.11 |
| AVG Volume (30 Days) | 987.0K | ★ 2.3M |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $410,212,000.00 | $158,182,000.00 |
| Revenue This Year | $9.80 | $53.52 |
| Revenue Next Year | $7.11 | $27.10 |
| P/E Ratio | $64.39 | ★ N/A |
| Revenue Growth | 16.47 | ★ 20.60 |
| 52 Week Low | $20.48 | $5.64 |
| 52 Week High | $43.16 | $13.20 |
| Indicator | IMAX | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 82.69 |
| Support Level | $35.94 | $6.40 |
| Resistance Level | $43.16 | N/A |
| Average True Range (ATR) | 1.68 | 0.77 |
| MACD | 0.27 | 0.65 |
| Stochastic Oscillator | 66.11 | 99.73 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.